| C03BA11 |
Indapamide |
Pisizif SR |
Prolonged release tablet |
1.5 |
mg |
30 |
Чайкафарма Висококачествените лекарства АД, България |
1 |
tabl |
- |
5.86 |
0.11633 |
3.49 |
25% |
0.87 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 11/ 12,06,2009; № 24/ 31.07.2009; № 94/ 23.06.2010; № 109/ 11.10.2010;Протокол 58/13.03.2014; КП-52/21.06.2018 и НСР-15497/26.04.2018 |
02.06.2019 |
08.09.2012 |
|
Активен |
425 |
| C03BA11 |
Indapamide |
RAWEL SR |
Prolonged release tablet |
1.5 |
mg |
90 |
KRKA, d.d., Словения |
1 |
tabl |
- |
14.42 |
0.11633 |
10.47 |
25% |
2.61 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 92/ 23.06.2010; № 109/ 11.10.2010; НСР-141/07.06.2013;Протокол 58/13.03.2014; НСР-8299/26.02.2016 |
02.04.2016 |
08.09.2012 |
|
Заличен |
1856 |
| C03BA11 |
Indapamide |
RAWEL SR |
Prolonged release tablet |
1.5 |
mg |
30 |
KRKA, d.d., Словения |
1 |
tabl |
- |
3.49 |
0.11633 |
3.49 |
25% |
0.87 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 11/ 12,06,2009; № 24/ 31.07.2009; № 94/ 23.06.2010; № 109/ 11.10.2010; № 152/14.03.2011; НСР-895/09.08.2013;Протокол 58/13.03.2014; НСР-4919/22.10.2014.; НСР-7852/15.01.2016. |
02.06.2019 |
08.09.2012 |
|
Активен |
3292 |
| C03BA11 |
Indapamide |
Sophtensif |
Film coated tablet |
2.5 |
mg |
30 |
Софарма АД, България |
1 |
tabl |
- |
6.1 |
0.11633 |
3.49 |
25% |
0.87 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 11/ 12,06,2009; № 24/ 31.07.2009; № 94/ 23.06.2010; № 109/ 11.10.2010;Протокол 58/13.03.2014 |
02.06.2019 |
08.09.2012 |
|
Активен |
163 |
| C03BA11 |
Indapamide |
Sophtensif |
Prolonged release tablet |
1.5 |
mg |
30 |
Софарма АД, България |
1 |
tabl |
- |
4.24 |
0.11633 |
3.49 |
25% |
0.87 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-12947/08.06.2017 |
02.06.2019 |
|
|
Активен |
2547 |
| C03BA11 |
Indapamide |
Sophtensif |
Prolonged release tablet |
1.5 |
mg |
30 |
Софарма АД, България |
1 |
tabl |
- |
4.24 |
0.14133 |
4.24 |
25% |
1.06 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
НСР-2612/03.02.2014; НСР-2813/21.02.2014; НСР-3106/21.03.2014;Протокол 58/13.03.2014; HCP-5715/26.02.2015. |
16.03.2015 |
|
|
Заличен |
2547 |
| C03BA11 |
Indapamide |
Tertensif SR |
Prolonged release tablet |
1.5 |
mg |
30 |
Les Laboratoires Servier, Франция |
1 |
tabl |
- |
7.01 |
0.11633 |
3.49 |
25% |
0.87 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 11/ 12,06,2009; № 24/ 31.07.2009; № 94/ 23.06.2010; № 109/ 11.10.2010;Протокол 58/13.03.2014; НСР-1894/27.11.2013 , НСР-4913/22.10.2014 и КП-107/06.04.2015., КП-116/06.04.2015; НСР-9970/29.07.2016; НСР-14317/03.11.2017; НСР-17888/07.02.2019 |
02.06.2019 |
08.09.2012 |
|
Активен |
3749 |
| C03BA11 |
Indapamide |
TevaIndam |
Prolonged release tablet |
1.5 |
mg |
30 |
Teva B.V., Нидерландия |
1 |
tabl |
- |
4.2 |
0.11633 |
3.49 |
25% |
0.87 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2 |
№ 208/ 04.11.2011; КЦРР-1852/12.12.2012 г;Протокол 58/13.03.2014; НСР-11569/26.01.2017 г. |
02.06.2019 |
08.09.2012 |
|
Активен |
1508 |
| C03CA01 |
Furosemide |
C03CA01 Furosemide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C03CA01 |
Furosemide |
FUROSER |
Solution for injection |
10 mg/ml - 2 ml |
mg |
10 |
Чайкафарма Висококачествените лекарства АД, България |
40 |
mg |
- |
17.7 |
3.54 |
17.7 |
50% |
8.85 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,N18.0,N18.8 |
НСР-5268/10.12.2014. |
02.01.2015 |
08.09.2012 |
|
Заличен |
572 |
| C03CA01 |
Furosemide |
C03CA01 Furosemide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C03CA01 |
Furosemide |
Furantril |
Tablet |
40 |
mg |
12 |
Актавис EАД, България |
40 |
mg |
- |
1.36 |
0.0565 |
0.68 |
50% |
0.34 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
НСР-6386/03.06.2015.; КП-76/05.10.2018 и НСР-16486/17.08.2018 |
02.11.2018 |
|
|
Активен |
91 |
| C03CA01 |
Furosemide |
Furantril |
Tablet |
40 |
mg |
12 |
Актавис EАД, България |
40 |
mg |
- |
1.44 |
0.04667 |
0.56 |
50% |
0.28 |
|
I10,I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,N18.0,N18.8 |
НСР-6385/03.06.2015 |
02.07.2015 |
|
|
Заличен |
91 |
| C03CA01 |
Furosemide |
Furosemide Sopharma |
Tablet |
40 |
mg |
20 |
Софарма АД, България |
40 |
mg |
- |
1.13 |
0.0565 |
1.13 |
50% |
0.56 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
НСР-6575/29.06.2015. |
02.07.2015 |
|
|
Активен |
4027 |
| C03CA04 |
Torasemide |
C03CA04 Torasemide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C03CA04 |
Torasemide |
TORAZIDEX |
Tablet |
5 |
mg |
30 |
Sandoz d.d., Словения |
15 |
mg |
- |
6.73 |
0.505 |
5.05 |
50% |
2.53 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
№ 162/ 20.04.2011; НСР-817/07.08.2013; НСР-3283/24.04.2014; НСР-8366/26.02.2016; НСР-13345/28.07.2017; НСР-15798/08.06.2018 |
02.07.2018 |
08.09.2012 |
|
Активен |
2728 |
| C03CA04 |
Torasemide |
TORAZIDEX |
Tablet |
10 |
mg |
30 |
Sandoz d.d., Словения |
15 |
mg |
- |
11.63 |
0.505 |
10.1 |
50% |
5.05 |
|
I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
№ 162/ 20.04.2011; НСР-15798/08.06.2018 |
02.07.2018 |
08.09.2012 |
|
Активен |
997 |
| C03CA04 |
Torasemide |
Torsit SR |
Prolonged release tablet |
5 |
mg |
30 |
Унифарма ООД, България |
15 |
mg |
- |
5.05 |
0.505 |
5.05 |
50% |
2.53 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
КЦРР-1662/20.11.2012 г.; НСР-898/09.08.2013; НСР-2964/07.03.2014; НСР-4930/22.10.2014; HCP-10138/31.08.2016 |
02.10.2016 |
|
|
Активен |
3317 |
| C03CA04 |
Torasemide |
Torsit SR |
Prolonged release tablet |
10 |
mg |
30 |
Унифарма ООД, България |
15 |
mg |
- |
10.1 |
0.505 |
10.1 |
50% |
5.05 |
|
I11.0,I12.0,I13.0,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
КЦРР-1662/20.11.2012 г. НСР-899/09.08.2013; НСР-2964/07.03.2014 |
02.04.2014 |
|
|
Активен |
2096 |
| C03CA04 |
Torasemide |
TRIFAS |
Tablet |
10 |
mg |
30 |
Menarini International Operations Luxembourg S.A., Люксембург |
15 |
mg |
- |
13.09 |
0.505 |
10.1 |
50% |
5.05 |
|
I50.0,I50.1 |
№ 66/ 08.04.2010; № 77/ 22.04.2010; № 85/17.06.2010 |
02.10.2013 |
08.09.2012 |
|
Активен |
537 |
| C03CA04 |
Torasemide |
TRIFAS COR |
Tablet |
5 |
mg |
30 |
Menarini International Operations Luxembourg S.A., Люксембург |
15 |
mg |
- |
8.74 |
0.505 |
5.05 |
50% |
2.53 |
|
I50.0,I50.1 |
№ 66/ 08.04.2010; № 77/ 22.04.2010; № 85/17.06.2010 |
02.10.2013 |
08.09.2012 |
|
Активен |
536 |
| C03DA01 |
Spironolactone |
C03DA01 Spironolactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C03DA01 |
Spironolactone |
SPIRONOLACTON ACTAVIS |
Coated tablet |
25 |
mg |
30 |
Актавис EАД, България |
75 |
mg |
- |
5.08 |
0.34175 |
3.42 |
25% |
0.86 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
|
16.12.2014 |
08.09.2012 |
|
Активен |
235 |
| C03DA01 |
Spironolactone |
Spironolactone Accord |
Film coated tablet |
25 |
mg |
30 |
Accord Healthcare Limited, Обединено Кралство |
75 |
mg |
- |
5.34 |
0.34175 |
3.42 |
25% |
0.85 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
НСР-16552/24.08.2018 |
02.10.2018 |
|
|
Активен |
16236 |
| C03DA01 |
Spironolactone |
Spironolactone Accord |
Film coated tablet |
50 |
mg |
30 |
Accord Healthcare Limited, Обединено Кралство |
75 |
mg |
- |
12.01 |
0.34175 |
6.84 |
25% |
1.71 |
|
I11.0,I11.9,I12.0,I12.9,I13.0,I13.1,I13.2,I50.0,I50.1,K74.0,K74.3,K74.4,K74.5,K74.6,N18.0,N18.8 |
НСР-16552/24.08.2018 |
02.10.2018 |
|
|
Активен |
16237 |